About OcuMension
OcuMension is a publicly listed company based in Shanghai (China) founded in 2017. Ophthalmic drugs for eye disorders are developed. The company has 489 employees. Its focus areas include Life Sciences, Ophthalmology, Drugs and Diversified.
Company details
Founded in 2017 and based in Shanghai, China, operations are focused on the ophthalmology sector. A platform for eye medicine development is maintained, with lead candidates including intravitreal implants for uveitis, nitric oxide-based treatments for glaucoma, and therapies for allergic conjunctivitis and macular degeneration. Additional pipeline items address postoperative inflammation, dry eye, blepharitis, ocular hypertension, bacterial infections, corneal rejection, and optic neuritis.
- Headquarters Shanghai, China
- Employees 489
- Stage Public
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website ocumension.com/cn/index.html
- Legal Name Ocumension Therapeutics
- Annual Revenue$112.07 M (USD)92.8as on Dec 31, 2025
- Net Profit-$22.13 M (USD)40.78as on Dec 31, 2025
- EBITDA-$2.29 M (USD)92.44as on Dec 31, 2025
- Employee Count489
People of OcuMension
2 people are tracked at OcuMension (1 in leadership, 1 in team); the tracked headcount is 489.
| Name | Role | Group |
|---|---|---|
Judy Judy | Medical Director | Leadership |
Yuan Zhang | Medical Manager | Team |
Complete people profiles for OcuMension
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of OcuMension
OcuMension is a publicly listed company on the HKEX with ticker symbol 1477 in Hong Kong, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date10 Jul 2020
- Listed onHKG: 1477
- Listed entityOcumension Therapeutics
- Exchange sectorHealth technology
- ISINKYG674111011
- Share price4.89 HKD (-0.2% on the day) · 2026-10-14
- Market capitalisation3,995,374,065.00 HKD
- EPS (diluted, trailing year)-0.18 HKD
- Volume (last session)198,500
Financials of OcuMension
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 872.3M HKD | -172.2M HKD | -17.9M HKD |
| 2024 | 452.4M HKD | -290.9M HKD | -236.2M HKD |
| 2023 | 272.2M HKD | -419.7M HKD | -380.8M HKD |
| 2022 | 184.8M HKD | -468.2M HKD | -483.5M HKD |
| 2021 | 67.7M HKD | -313.4M HKD | -448.4M HKD |
Detailed financial statements for OcuMension
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Ocumension
Complete news archive for OcuMension
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about OcuMension
OcuMension was founded in 2017.
OcuMension is headquartered in Shanghai, China.
OcuMension has 489 employees.
Annual revenue of OcuMension is $112.07M as on Dec 31, 2025.
Founded in 2017 and based in Shanghai, China, operations are focused on the ophthalmology sector. A platform for eye medicine development is maintained, with lead candidates including intravitreal implants for uveitis, nitric oxide-based treatments for glaucoma, and therapies for allergic conjunctivitis and macular degeneration. Additional pipeline items address postoperative inflammation, dry eye, blepharitis, ocular hypertension, bacterial infections, corneal rejection, and optic neuritis.
Yes, OcuMension is publicly traded on HKEX under the ticker symbol 1477.